Developments in antimicrobial resistance and treatment

Future Microbiology

Volumn 6, Issue 7, 2011, Pages 715-720

  Bryan, Jenny ^a  

^a Medical Writer   (United Kingdom)

Author keywords

Asia Pacific; carbapenemases; carbapenems; Gram negative resistance; NDM 1 carbapenemases

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CARBAPENEM; CEFEPIME; CEPHALOSPORIN; CLAVULANIC ACID; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; IMIPENEM; MEROPENEM; METALLO BETA LACTAMASE; NITROFURANTOIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN; VANCOMYCIN;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; COMMUNITY ACQUIRED PNEUMONIA; CONFERENCE PAPER; GOVERNMENT; HEALTH CARE POLICY; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL INFECTION; HUMAN; MEDICAL RESEARCH; MONITORING; MORTALITY; PRIORITY JOURNAL; PUBLISHING; SCIENTIST; SOUTH KOREA; SYMPOSIUM; TRACHEOBRONCHITIS; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; WORLD HEALTH ORGANIZATION;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY; HUMANS;

NEGIBACTERIA;

EID: 79961062847     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.11.57     Document Type: Conference Paper

References (24)

1. Chen YH, Hsueh PR, Badal RE et al. Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria. J. Infect. 62(4), 280-291 (2011).
2. Badal R, Hoban D, Bouchillon S et al. Klebsiella pneumoniae from intraabdominal infections in Asia/Pacific in 2009-2010: susceptibility and incidence of EBSL phenotypes. Presented at: 8th International Symposium on Antimicrobial Agents and Resistance (ISAAR). Seoul, South Korea, 6-8 April 2011.
3. Badal R, Lob S, Hoban D et al. Trends in levofloxacin and ciprofloxacin resistance rates in E. coli from intra-abdominal infections in Asia/Pacific-SMART 2005-present. Presented at: 8th International Symposium on Antimicrobial Agents and Resistance (ISAAR). Seoul, South Korea, 6-8 April 2011.
4. Badal R, Hoban D, Bouchillon S et al. Acinetobacter baumanii susceptibility: global and regional analysis from SMART, 2002-present. Presented at: 8th International Symposium on Antimicrobial Agents and Resistance (ISAAR). Seoul, South Korea, 6-8 April 2011.
5. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum b-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J. Antimicrob. Chemother. 60(5), 913-920 (2007). (Pubitemid 47617735)
6. Paterson DL, Ko WC, Von Gottberg A et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum b-lactamases. Clin. Infect. Dis. 39(1), 31-37 (2004). (Pubitemid 38879546)
7. Lee NY, Huang WH, Tsui KC et al. Carbapenem therapy for bacteremia due to extended-spectrum b-lactamase-producing Escherichia coli or Klebsiella pneumoniae. Diagn. Microbiol. Infect. Dis. 70(1), 150-153. (2011).
8. Eagye KJ, Nicolau DP. Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 years is not associated with the use of ertapenem. J. Antimicrob. Chemother. 66(6), 1392-1395 (2011).
9. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect. Dis. 11(5), 355-362 (2011).
10. Chen Y, Zhou Z, Jiang Y, Yu Y. Emergence of NDM-1-producing Acinetobacter baumannii in China. J. Antimicrob. Chemother. 6(66), 1255-1259 (2011).
11. Krüger S, Ewig S, Marre R et al. CAPNETZ Study Group. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur. Respir. J. 31(2), 349-355 (2008).
12. Musher DM, Rueda AM, Kaka AS, Mapara SM. The association between pneumococcal pneumonia and acute cardiac events. Clin. Infect. Dis. 45(2), 158-165 (2007). (Pubitemid 47041005)
13. American Thoracic Society; Infectious Diseases Society of America: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171(4), 388-416 (2005).
14. Nicasio AM, Eagye KJ, Nicolau DP et al. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J. Crit. Care 25(1), 69-77 (2010).
15. Kumar A, Zarychanski R, Light B et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit. Care Med. 38(9), 1773-1785 (2010).
16. Kett DH, Cano E, Quartin AA et al.; Improving Medicine Through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Investigators: Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. Lancet Infect. Dis. 11(3), 181-189 (2011).
17. Bouadma L, Luyt CE, Tubach F et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 375(9713), 463-474 (2010).
18. Dallas J, Skrupky L, Abebe N et al. Ventilator-associated tracheobronchitis in a mixed surgical and medical ICU population. Chest 139(3), 513-518 (2011).
19. Shindo Y, Sato S, Maruyama E et al. Health-care-associated pneumonia among hospitalized patients in a Japanese community hospital. Chest 135(3), 633-640 (2009).
20. Park HK, Song JU, Um SW et al. Clinical characteristics of health care-associated pneumonia in a Korean teaching hospital. Respir. Med. 104(11), 1729-1735 (2010).
21. Maruyama T, Niederman MS, Kobayashi T et al. A prospective comparison of nursing home-acquired pneumonia with hospital-acquired pneumonia in non-intubated elderly. Respir. Med. 102(9), 1287-1295 (2008).
22. Seymann GB, Di Francesco L, Sharpe B et al. The HCAP gap: differences between self-reported practice patterns and published guidelines for health care-associated pneumonia. Clin. Infect. Dis. 49(12), 1868-1874 (2009).
23. El-Solh AA, Peter M, Alfarah Z et al. Antibiotic prescription patterns in hospitalized patients with nursing home-acquired pneumonia. J. Hosp. Med. 5(3), E5-E10 (2010).
24. Brito V, Niederman MS. Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia. Curr. Opin. Infect. Dis. 22(3), 316-325 (2009).